What is the role of myelosuppressive therapy in the treatment of chronic myelogenous leukemia (CML)?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print
Answer

Myelosuppressive therapy was formerly the mainstay of treatment to convert a patient with CML from an uncontrolled initial presentation to one with hematologic remission and normalization of the physical examination and laboratory findings. However, it may soon fall out of favor as the new agents prove to be more effective, with fewer adverse events and longer survival.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!